Quickly verify claims by accessing the underlying experimental data and figures.
Press Enter β΅ to solve
Fuel Your Discoveries
"Science is organized knowledge. Wisdom is organized life."
- Immanuel Kant
Quick Explanation
Copied
BGPT Review
Key claim: endogenous U2AF1 missense mutations (notably S34F and I24T) can rescue deleterious KRAS exon skipping caused by specific KRAS mutations (G12S and Q61R/L) in lung and pancreatic cancer contexts, restoring MAPK signaling and growth, and showing strong mutation co-enrichment patterns in large cancer cohorts.
Core evidence includes (i) endogenous-locus prime editing, (ii) RNA-seq/RT-PCR splicing quantification (KRAS exon 2 and exon 3), (iii) mechanistic RNA-binding targeting experiments (dCasRx steric-hindrance model), and (iv) cohort odds-ratio + VAF + survival stratification.
Major skeptical caveats: strong mechanistic plausibility, but causality in tumors still relies on limited cell-line models and correlational clinical analyses; exon skipping quantification and selection inference could be sensitive to cohort preprocessing and splicing-caller choices.
Long Explanation
Paper Review (Preprint): βU2AF1 mutations rescue deleterious exon skipping induced by KRAS mutationsβ
Thesis: Oncogenic KRAS mutations create splicing defects (KRAS exon 2 skipping for G12S; exon 3 skipping for Q61R/L), and specific U2AF1 mutations can compensate by restoring correct KRAS isoform splicing, increasing MAPK pathway signaling and cell fitness. The authors further argue this creates a βcascading selectionβ pattern in cancer genomes.
1) Mechanism map (visual)
The diagram summarizes the paperβs proposed causal chain; see sections 2β4 for the supporting experimental and cohort evidence.
2) Core experimental causal evidence: exon skipping is KRAS-mutationβdependent and U2AF1-rescuable
Endogenous locus engineering: The authors use twin prime editing to introduce multiple amino-acid substitutions at U2AF1 S34 (including S34S, S34C, S34A, S34Y, S34F, and S34F with an alternative codon).
Splicing phenotype: In parental or U2AF1 S34S-mutant A549 cells, KRAS exon 2 skipping is reported with median ~18% of reads (range 12β32%), while it drops to median ~3% (range 0β10%) in U2AF1 S34F/S34F(TTC) cells.
Back-edit rescue: βBack-editingβ the S34F allele to wild type restores exon skipping toward baseline (~18% of reads).
Cell-line context sensitivity: In NCI-H441 (which differs by KRAS allele: G12V rather than G12S), the authors report no exon 2 skipping regardless of U2AF1 mutational status.
The bar plot uses the paperβs reported medians (~18% vs ~3%). Range variability is noted in the text but not plotted here to avoid over-interpreting distributional shape.
2.2 KRAS exon 2 skipping depends on creating a cryptic U2AF1 binding site (not simply the amino-acid change)
The paper states the KRAS G12S RNA sequence resembles a U2AF1 binding site and creates a UAG trinucleotide predicted to be bound by wildtype U2AF1 but not by U2AF1 S34F.
Prime editing is used to change the KRAS G12S codon to alternative serine codons (AGTβTCT) that do not resemble a U2AF1 binding site; exon 2 skipping is reported as abolished under the βno-cryptic-siteβ codon configuration.
To test steric-hindrance logic, the authors target catalytically inactive dCasRx to the canonical 3' splice site versus the G12 sequence and report that targeting the G12 sequence can induce exon 2 skipping, consistent with steric interference between proximal/alternative binding events.
3.1 SSOs that induce exon skipping reduce signaling readouts and growth
The authors use splice-switching oligonucleotides (SSOs) to induce KRAS exon 2 skipping and report a dose-dependent increase in skipping in NCI-H23 (KRAS G12C) and concurrent reductions in p-Erk, p-Akt, and full-length KRAS protein.
They also grow SSO-treated cells on ultra-low attachment plates and report that even small increases in exon 2 skipping reduce cell growth.
3.2 Implication: KRAS exon skipping is βcounter-selectedβ unless a splicing-factor mutation rescues it
The authorsβ central selection model depends on: (i) exon skipping limiting KRAS signaling; (ii) specific U2AF1 mutations reversing exon skipping; (iii) strong mutation co-enrichment between KRAS mutations that produce skipping and U2AF1 mutations that rescue.
4.1 U2AF1 S34F is strongly enriched in KRAS G12S lung adenocarcinoma
The authors analyze 76,917 LUAD cases (62,009 Foundation Medicine + 14,908 AACR Project GENIE) and report that KRAS G12S has an odds ratio 7.4 for co-occurrence with U2AF1 S34F, with p = 4.8 Γ 10^-73.
They also report positive correlation between KRAS G12S and U2AF1 S34F VAFs in 43 tumor samples without CNVs, with KRAS VAF higher than U2AF1 S34F, consistent with U2AF1 arising secondarily (though this is still an inference).
Survival association: in MSK-CHORD (5,777 patients), they report that acquisition of U2AF1 S34F in KRAS G12S-mutant tumors is associated with reduced overall survival.
This odds ratio is reported directly in the paper; confidence in causal direction is still limited by the observational nature of co-occurrence calculations.
The authors identify KRAS Q61R as associated with KRAS exon 3 skipping and show that multiple Q61 mutations (Q61R, Q61L, Q61H; and Q61K discussed in relation to silent mutations) are observed with exon 3 skipping in TCGA-based exon skipping analysis.
Mechanistic rescue: expressing U2AF1 I24T in KRAS Q61R-mutant Panc 02.13 cells increases KRAS exon 3 inclusion from ~66% to ~83% of transcripts; U2AF1 S34F did not rescue in that experiment, and wildtype U2AF1 produced a smaller effect.
Cohort enrichment: in pancreatic cancers, they report an odds ratio of 46.6 for co-occurrence of U2AF1 I24T with KRAS Q61R and 25 for U2AF1 I24T with KRAS Q61L, markedly higher than for other Q61 pairings.
Only OR values explicitly stated are shown; p-values and CIs are not plotted to avoid implied precision.
6) Skeptical critique: what is strong, what is uncertain, what could mislead
6.1 Strengths
Within-locus editing logic is a major plus: endogenous prime editing of U2AF1 S34 and KRAS codon configuration is used to distinguish amino-acid effects from RNA-sequence cryptic-site effects.
Multiple orthogonal splicing assays are used (RNA-seq quantified PSI-like fractions and RT-PCR quantification; plus dCasRx position targeting).
Mechanistic inference uses spatial perturbation (dCasRx at/near splice-relevant RNA regions), which reduces (but does not eliminate) the likelihood that the effect is indirect.
Large cohort co-occurrence signals (ORs, VAF correlation hierarchy) are consistent with a βsecondary compensationβ modelβi.e., splicing-rescuing splicing-factor mutations are enriched specifically where oncogenic KRAS creates splicing defects.
6.2 Key uncertainties / blind spots
Clinical causality vs correlation: Survival associations are consistent with the model, but survival differences are multifactorial (tumor microenvironment, treatment heterogeneity, additional mutations). The preprint uses cohort stratification; causality cannot be proven solely from odds ratios + survival curves.
Model system dependence: Exon skipping rescue is demonstrated in a limited set of lung cancer lines (e.g., A549, NCI-H441) and a pancreatic line (Panc 02.13). Cell-line-specific RNA-binding context, chromatin/spliceosome composition, and mutant copy-number states may alter magnitude and generality.
Splicing quantification sensitivity: The paper uses rMATS/FDR-based event calling and read-fraction quantification. Splicing callers can differ in junction sensitivity, and filtering thresholds can affect detected events (especially low-coverage exon inclusion).
Mechanistic granularity is incomplete: The cryptic-binding-site/steric-hindrance model is experimentally supported by codon recoding and dCasRx positional perturbations, but the exact spliceosomal kinetics, whether multiple factors contribute, and how U2AF1 S34F/I24T change local recognition (vs broader transcriptome remodeling) remains to be mapped at high resolution.
Selection inference may be confounded: VAF ordering is consistent with secondary rescue, but copy-number changes, tumor purity differences, and sampling timepoints can bias VAF comparisons. The paper partially addresses CNVs by selecting cases lacking CNVs at loci (as stated), but residual confounding can remain.
7) Reproducibility notes (from the provided text)
Data availability: RNA-seq data to GEO; unique plasmids to Addgene.
Code availability: no original code reported.
8) BGPT-directed next steps (not medical; only science)
What would most efficiently test the model further?
Generalize across more genetic backgrounds: Re-engineer KRAS G12S/TCT in additional LUAD lines with differing spliceosomal states and test whether U2AF1 S34F consistently rescues KRAS exon 2 inclusion and growth phenotypes.
Directly quantify U2AF1 binding at the cryptic site: Use approaches that measure protein-RNA association to test whether S34F reduces occupancy at the cryptic site and increases canonical splice-site utilization; the paper provides a functional steric argument but not direct occupancy measurements.
Dissect whether U2AF1 has rescue-only vs broad transcriptome effects: Determine if rescue of KRAS exon inclusion correlates with a global rollback of the U2AF1 S34F splicing program or if KRAS-specific rescue is sufficient for growth.
Author reviews to explore next
Feedback:
Updated: April 08, 2026
BGPT Paper Review
Study Novelty
90%
The preprint connects specific KRAS-mutantβdriven cryptic splicing defects to compensatory U2AF1 missense rescue using endogenous-locus prime editing and positional RNA-targeting, framed as cascading selection. This βsplicing-factor rescue of oncogene-induced mis-splicingβ is presented as a first/rare mechanistic class, beyond descriptive co-occurrence correlations.
Scientific Quality
80%
Strengths: strong internal causal chain (engineer KRAS/U2AF1 β quantify exon skipping β perturb RNA binding position β rescue). Weaknesses/limits: remaining dependence on limited cell lines; mechanistic model is inferred rather than directly measuring U2AF1 occupancy kinetics; patient-level claims are observational. Code availability is not provided in the text.
Study Generality
70%
The specific mechanisms (U2AF1 S34F with KRAS G12S exon 2; U2AF1 I24T with KRAS Q61R/L exon 3) are specific, but the broader frameworkβsplicing-factor mutations selected to correct oncogene-induced splicing defectsβcould generalize. Evidence for wider generality is currently indirect (the paper speculates more cases may exist).
Study Usefulness
80%
Provides a detailed mechanistic hypothesis and testable framework for variant interpretation in cancer genomics (KRAS variant + U2AF1 variant context). It also suggests splicing-factor mutation status could stratify prognosis/biology, though therapeutic implications are not directly tested here.
Study Reproducibility
70%
Experimental methods are described (cell culture, twin prime editing strategy, RNA-seq pipeline components, rMATS-based event calling, RT-PCR quantification). Data availability for RNA-seq to GEO and plasmids to Addgene is stated, but original code is not provided and the preprint is not fully validated via independent replication in additional models within the provided text.
Explanatory Depth
80%
The paper offers mechanistic reasoning linking nucleotide-level cryptic site creation to local steric effects and splice-site utilization, then connects that to pathway readouts and selection in cohorts. Direct biochemical confirmation of local U2AF1 binding changes is not shown in the provided text, limiting maximum mechanistic certainty.
It loads rMATS/PSI-like exon inclusion fractions from the preprintβs GEO RNA-seq and compares KRAS exon 2/3 PSI across edited U2AF1 and KRAS genotypes to validate effect sizes and statistics.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
A βpurely protein-level KRAS effectβ model (where the amino-acid substitution alone causes exon skipping) is less likely because codon recoding that removes the cryptic motif abolishes exon skipping as reported; however, without direct motif occupancy measures the model cannot be fully ruled out.
A βglobal transcriptional stressβ model is less likely because the paper attempts to localize the cause to steric interference by dCasRx positional targeting, but global transcriptome remodeling effects may still contribute to magnitude; thus this remains partially plausible as a secondary factor.
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Fuel Your Discoveries
Ask a Follow-Up
Key Insight
